Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Priorix versus M-M-RVAXPRO immunogenicity and safety study in toddlers
2011-004905-26Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2012
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of measles, mumps and rubella vaccine (live) and M-M-R II in measles, mumps and rubella (2 arms), sponsored by GSK. Primary endpoint: Seroresponse rates to measles, mumps, and rubella at Day 42. Started Oct 2012; status: completed.
02
Drugs
measles, mumps and rubella vaccine (live)M-M-R II
03
Conditions
measlesmumpsrubella
Beyond the preview
Go deeper on 2011-004905-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004905-26.